By
Drug Target Review2024-06-24T12:00:27
A novel screening tool may increase the five-year survival rate of hepatocellular carcinoma patients to 90 percent.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2025-06-11T14:00:00
Sponsored by Eurofins Discovery
2024-01-26T13:22:42
Sponsored by bit.bio
2024-01-10T08:56:17
Sponsored by Leica Microsystems
2023-03-07T10:55:58
Sponsored by Agilent
2024-05-07T13:11:19
Sponsored by BellBrook Labs
2025-09-18T12:00:00
Sponsored by Benchling
Site powered by Webvision Cloud